Glioblastoma Multiforme News and Research

RSS

Glioblastoma Multiforme is a fast-growing type of central nervous system tumor that forms from glial (supportive) tissue of the brain and spinal cord and has cells that look very different from normal cells. Glioblastoma multiforme usually occurs in adults and affects the brain more often than the spinal cord. Also called GBM, glioblastoma, and grade IV astrocytoma.

Novel device enhances efficacy of standard chemotherapy

NovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients.

24 Nov 2008

Anti-brain tumor agent derived from herpes virus passes next hurdle

An anti-brain tumor agent developed from a genetically engineered herpes simplex virus has been shown to be safe when given in two doses and injected directly into the brain of patients with malignant glioma.

6 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

The Cancer Genome Atlas reports first results

The Cancer Genome Atlas (TCGA) has reported results from its first comprehensive study which focused on the deadly brain cancer glioblastoma.

8 Sep 2008

Celldex Therapeutics vaccine may double survival in patients with deadly brain tumors

A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may stave off recurrence and more than double survival in patients, according to a new study led by researchers in Duke's Preston Robert Tisch Brain Tumor Center.

2 Jun 2008

BiPar Sciences presents data for novel DNA repair inhibitor

BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.

2 Jun 2008

Cytopia announces novel anti-cancer drug development collaboration

Cytopia Limited today announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest growing segments of the cancer drug market.

9 May 2008

Brain tumor surgery, depression and survival

Depression is one of the most common psychiatric disorders in the world today. It is estimated that in any given year, 5 to 9 percent of the US population is clinically depressed. Studies have shown that depression negatively affects the immunological system, alters the body's response to malignancy, and may influence behavioral factors that impact recovery from disease

29 Apr 2008

NovoCure presents results from breast cancer pilot study

NovoCure announced today that it presented the results from a single-arm pilot trial evaluating the Novo-TTF, a non-invasive portable medical device, combined with neo-adjuvant chemotherapy for the treatment of patients with locally advanced breast cancer.

15 Apr 2008

MRI opens up promising new avenues for non-invasive diagnoses and classification of cancer

Doctors diagnose and prescribe treatment for brain tumors by studying, under a microscope, tumor tissue and cell samples obtained through invasive biopsy or surgery.

25 Mar 2008

Glioblastoma multiforme responds to new treatment

One of the toughest cancers to treat effectively is glioblastoma multiforme (GBM), the most common form of primary brain cancer.

28 Feb 2008

Gene therapy - immune system discovery may lead to effective treatment for glioblastoma multiforme

A new gene therapy approach that attracts and "trains" immune system cells to destroy deadly brain cancer cells also provides long-term immunity, produces no significant adverse effects and -- in the process of destroying the tumor -- promotes the return of normal brain function and behavioral skills, according to a study conducted by researchers at Cedars-Sinai Medical Center's Board of Governors Gene Therapeutics Research Institute.

20 Feb 2008

Three-drug cocktail improves outcomes in glioblastoma multiforme

New research at Wake Forest University Baptist Medical Center suggests that a three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme (GBM), a type of brain tumor with a dismal prognosis.

2 Jan 2008

Avastin shows promise for brain cancer

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

17 Dec 2007

Drug study for brain cancer shows promising results

14 Dec 2007

Avastin (bevacizumab) shows promise in phase II study of glioblastoma multiforme

Genentech, Inc. has announced that both study arms of a randomized, multi-center Phase II clinical study of Avastin (bevacizumab) administered alone or in combination with irinotecan chemotherapy demonstrated encouraging six-month progression-free survival (PFS) and objective response rate in patients with relapsed glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

19 Nov 2007

Block buster cancer drug Avastin gives hope to brain tumor victims

According to a new study the blockbuster cancer drug Avastin has shown promising results in treating brain cancer victims.

19 Nov 2007

New view of lung cancer genome

An international team of scientists, supported in part by the National Human Genome Research Institute (NHGRI), one of the National Institutes of Health (NIH), have announced that its systematic effort to map the genomic changes underlying lung cancer has uncovered a critical gene alteration not previously linked to any form of cancer.

5 Nov 2007

Radiation plus chemo quadruples survival time for fatal brain cancer

Over four times as many patients with a rapidly fatal type of brain cancer, glioblastoma multiforme (GBM), who are treated with the chemotherapy drug temozolomide (TMZ) and radiation therapy, can live for four years after diagnosis, compared to those who receive only radiation treatment, according to updated results of a large, international trial presented at the Plenary I session on October 29, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

29 Oct 2007

Human cytomegalovirus may help doctors treat glioblastoma multiforme

A common human virus may prove useful in attacking the deadliest form of brain tumors, according to a study by researchers at Duke's Preston Robert Tisch Brain Tumor Center.

22 Oct 2007